1. Recent Articles

    1. Using Chemistry to Target Neuroblastoma.

      Using Chemistry to Target Neuroblastoma.

      ACS Chem Neurosci. 2017 Aug 11;:

      Authors: Hansen JN, Li X, Zheng YG, Lotta LT, Dedhe A, Schor NF

      Abstract Neuroblastoma is a cancer of the neural crest almost exclusively seen in childhood. While children with single, small primary tumors are often cured with surgery alone, the 65% of children with neuroblastoma whose disease has metastasized have less than a 50% chance of surviving five years after diagnosis.

      Read Full Article
      Mentions: Surgery ALK
    2. Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor.

      Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor.

      Pediatr Blood Cancer. 2017 Aug 09;:

      Authors: Ezekian B, Englum BR, Gulack BC, Rialon KL, Kim J, Talbot LJ, Adibe OO, Routh JC, Tracy ET, Rice HE

      Read Full Article
      Mentions: Surgery
    3. The heartbreaking reason behind this runner’s pink hair – and why you need to cheer him on in the Gloucester Marathon

      The heartbreaking reason behind this runner’s pink hair – and why you need to cheer him on in the Gloucester Marathon

      It will be hard to miss Nick Bird on Sunday

      Nick Bird

      Hundreds of runners will line up on Sunday ready to pound the streets in the Gloucester Marathon and Half Marathon but one runner will probably stand out more than the others.

      Nick Bird won’t be hard to miss with his pink top and hair to match.

      But there is a sad story behind his bright appearance.

      It’s been four years since Nick lost his precious son, Adam, to neuroblastoma – a rare and aggressive childhood cancer.

      Adam Bird

      Read Full Article
    4. Longitudinal parental preferences for late effects communication during cancer treatment

      Few studies have investigated parent preferences for late effects communication during pediatric cancer treatment. We used questionnaire data to assess whether parental preferences for late effects information change over the year after diagnosis. Most parents found this information to be very/extremely important at baseline, assessed soon after diagnosis, (94%, 153/162), 4 months (91%, 147/162), and 12 months (96%, 156/163).

      Read Full Article
      Mentions: Treatment
    5. Anti-GD2 immunotherapy for neuroblastomas.

      Anti-GD2 immunotherapy for neuroblastomas.

      Expert Rev Anticancer Ther. 2017 Aug 07;:

      Authors: Sait S, Modak SI

      Abstract INTRODUCTION: Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.

      Read Full Article
    6. Neurological Complications of Childhood Cancer.

      Neurological Complications of Childhood Cancer.

      Semin Pediatr Neurol. 2017 Feb;24(1):60-69

      Authors: Weaver L, Samkari A

      Abstract Though the treatment of pediatric cancers has come a long way, acute and chronic effects of cancer are still affecting the life of many children. These effects may be caused not only by the malignancy itself but also by the interventions used for the purpose of treatment.

      Read Full Article
    7. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    8. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

      Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

      BMC Cancer. 2017 Aug 04;17(1):520

      Authors: Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T

      Read Full Article
      Mentions: INRG Imaging MYCN
    9. Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo.

      Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo.

      Oncotarget. 2017 Jul 27;:

      Authors: Tümmler C, Snapkov I, Wickström M, Moens U, Ljungblad L, Elfman LHM, Winberg JO, Kogner P, Johnsen JI, Sveinbjørnsson B

      Read Full Article
    10. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

      Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

      Clin Nucl Med. 2017 Jul 29;:

      Authors: Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S

      Read Full Article
    11. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (7 articles) Treatment
    2. (4 articles) Immunotherapy
    3. (3 articles) Refractory
    4. (3 articles) Surgery
    5. (3 articles) Chemotherapy
  3. Recent Quotes

    1. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    2. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    3. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    4. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    5. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    6. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    7. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    8. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    9. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju
    10. The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases, Composition-of-matter and method-of-use patent applications have been filed on these and other additional targeted agents, as well as on the chemistry platform.
      By Prem Das